Genomics Inform Search


Genomics Inform > Volume 16(3); 2018 > Article
Park, Kim, Kim, Yun, Kim, Kim, Jeong, Kang, and Kim: Generation of Whole-Genome Sequencing Data for Comparing Primary and Castration-Resistant Prostate Cancer


Because castration-resistant prostate cancer (CRPC) does not respond to androgen deprivation therapy and has a very poor prognosis, it is critical to identify a prognostic indicator for predicting high-risk patients who will develop CRPC. Here, we report a dataset of whole genomes from four pairs of primary prostate cancer (PC) and CRPC samples. The analysis of the paired PC and CRPC samples in the whole-genome data showed that the average number of somatic mutations per patients was 7,927 in CRPC tissues compared with primary PC tissues (range, 1,691 to 21,705). Our whole-genome sequencing data of primary PC and CRPC may be useful for understanding the genomic changes and molecular mechanisms that occur during the progression from PC to CRPC.


Prostate cancer (PC) is the most common malignancy in males [1]. It is known that about 20% of PC patients experience disease progression and distant metastasis [2, 3]. The therapeutic options for patients with aggressive PC include prostatectomy, radiation therapy, and androgen deprivation therapy (ADT) [4]. Although ADT therapy induces short 2–3-year remissions, unfortunately, most PCs eventually progress into castration-resistant prostate cancer (CRPC) [3], which does not respond to ADT therapy and shows poor clinical behavior. Therefore, it is crucial to understand the molecular characteristics and identify robust biomarkers that are associated with the development of CRPC from primary PC.
High-throughput next-generation sequencing technologies have gradually uncovered the molecular characteristics of PC, along with CRPC [58]. However, many genomic studies on CRPC have been conducted on metastasized CRPC that has been discovered at distant organs. These studies of metastatic sites do not reflect the precise molecular characteristics of CRPC, because these sites are not the primary PC site and because metastatic sites have completely different microenvironments from the primary site [9]. Here, we generated a dataset of whole genomes from four pairs of primary PC and CRPC samples from the same patient (i.e., a total of eight paired samples from four PC patients). In this report, the genomic status of samples with primary PC and CRPC was explored, and different variants between these two distinct phenotypes were identified by comparing the genomes of primary PC and its paired CRPC.


Tissues samples

Four pairs of primary PC and CRPC tissues were obtained from Chungbuk National University Hospital (Korea) with informed consent and approval of the Internal Review Board at Chungbuk National University. To obtain a consistent variant profile that was associated with the development of CRPC, primary CRPCs were obtained from homogenous biopsy sites, and none of our PC samples was from distant metastatic sites. Detailed clinical characteristics of the four pairs of primary PC and CRPC tissues are described in Supplementary Table 1.

Whole-genome sequencing library construction and sequencing

Genomic DNA was isolated using the DNeasy Blood and Tissue kit (Qiagen, Carlsbad, CA, USA), and the sequencing library was constructed using the Illumina TruSeq DNA Library Prep Kit (San Diego, CA, USA). Next, paired-end sequencing was performed on an Illumina HiSeq X Ten sequencing instrument, yielding ~ 150-bp short sequencing reads.

Data analysis

The sequenced reads were aligned to human reference genome 19 using Burrows Wheelers Aligner [10], and duplicate reads were removed using Picard (Broad Institute). Then, the remaining reads were calibrated and realigned using the Genome Analysis Toolkit [11]. The realigned Binary Alignment Map files were analyzed using Strelka [12] to detect somatic single-nucleotide variants and insertions/ deletions. For all programs, the default parameter settings were applied.

Results and Discussion

Quality and quantity of the sequencing data

The whole-genome sequencing (WGS) data, including the mapping rate, genome coverage, scores of the mapping quality, and duplicate reads, are summarized in Table 1. Briefly, the mapping rate and scores of the mapping quality in the four pairs of primary PC and CRPC samples were higher than 95% and 53%, respectively. In addition, the average genome coverage of our samples was over 30× (between 31.81× and 53.54×). Although coverage of several hundred times is required for detecting low-level mutations in next-generation sequence data [13], WGS with 30× sequence coverage is appropriate for comprehensive identification of tumor-specific somatic mutations [14]. These results suggest that the quality and quantity of our sequencing data are adequate for mutational analysis during the progression from PC to CRPC.

Mutation patterns identified from CRPC compared with PC

The average number of somatic mutations per patients was 7,927 in CRPC tissues compared with primary PC tissues (range, 1691 to 21,705). In particular, patient P2 had hypermutations (n = 21,705), whereas patient P1 had a low mutation frequency (n = 1,691) (Fig. 1A). To observe the mutation signatures in the development of CRPC from primary PC, we examined the spectrum of base substitutions. This analysis revealed an unusually high proportion of C:G > T:A and A:T>G:C transversions (Fig. 1B), similar to a previous study [15]. Next, the mutated sites were annotated as non-synonymous, synonymous, stop, and gain mutations. The number of mutations affecting protein-coding genes was 9, 321, 22, and 10 for the four patients (Table 2), and we observed recurrent mutations in the ANKRD20A4, ANDRK38B, AQP7, GGT1, and TAS2R31 genes. Detailed information for the non-synonymous and recurrent mutations is summarized in Supplementary Table 2. Further study will be needed to examine whether the mutated genes are associated with the development of CRPC from primary PC.
In conclusion, PC is a heterogeneous disease and has various steps in its disease progression, including CRPC, the poorest prognostic status during the progression of PC. Understanding the molecular characteristics of the development of CRPC will help identify high-risk PC patients and develop novel therapeutic strategies to block the progression of CRPC. We generated a set of WGS data, consisting of eight PC samples containing four pairs of primary PC and CRPC samples from the same patient, because genetic mutations have the greatest potential to play a role in the progression of PC and CRPC and the therapeutic management of CRPC [16, 17]. By comparing primary PC and its paired CRPC, many somatic mutations that were significantly associated with the development of CRPC were identified, including TP53 and KMT2C, which are known to be involved in the progression of PC [16, 17]. We hope that our whole-genome sequence data of the four paired PC and CRPC tissues will be utilized by many researchers to understand the progression of PC and the resistance to androgen deprivation therapy.


Availability: The whole-genome data are available in the Korean Bioinformation Center (KOBIC) biodata ( public database under accession numbers KBRS20180406_0000001KBRS20180406_0000008.

Authors’ contribution

Conceptualization: SYK

Sample and data curation: SJY, WJK, WTK, PJ, HWK

WGS data generation: JHK, PJ

Data analysis: JLP, SKK

Writing – original draft: JLP, SKK

Writing – review & editing: SYK


This research was supported by a National Research Foundation of Korea (NRF) grant (NRF-2014M3C9A3068 554 and NRF-2017MBA9B5060884), funded by the Korean government (MEST), and a grant from the KRIBB Research Initiative Program.

Supplementary Materials

Supplementary data including two tables can be found with this article online at

Fig. 1
Number of mutations and distribution of mutation type. (A) Somatic mutations were detected using the Strelka package with default parameter settings. (B) Relative distribution of single-base substitutions by type in each of the four paired castration-resistant prostate cancer patients. SNV, single nucleotide variant.
Table 1
Quality and quantity of the sequencing data
Sample ID Total No. of reads Mapped reads, n/% Duplicate reads, n/% Genome coverage (mean) Mapping quality
P1_PC 848,047,506 808,804,115/95.37 68,671,081/8.10 37.89 54.01
P1_CRPC 948,133,472 906,103,176/95.57 261,605,851/27.59 42.86 54.05
P2_PC 850,014,794 812,799,767/95.62 132,111,659/15.54 38.24 54.10
P2_CRPC 1,119,621,752 1,074,841,222/96.00 178,460,836/15.94 50.85 54.32
P3_PC 873,087,626 831,226,978/95.21 219,433,437/25.13 39.29 54.05
P3_CRPC 1,217,525,626 1,164,525,389/95.65 182,382,654/14.98 53.54 53.79
P4_PC 740,468,590 703,382,210/94.99 138,235,516/18.67 31.81 53.21
P4_CRPC 915,523,140 875,358,078/95.40 215,503,940/23.49 41.39 54.03
Table 2
Summary of mutation in exonic regions
Sample ID Synonymous mutations Non-synonymous mutations Stop or gain Mutated genes
P1 3 6 0 9
P2 104 226 10 321
P3 11 13 0 22
P4 3 8 1 10


1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
crossref pmid
2. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists’ Collaborative Group. Lancet 1995;346:265–269.
3. Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS. Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov 2016;15:699–718.
crossref pmid pdf
4. Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014;15:e404–e414.
crossref pmid
5. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11–22.
crossref pmid pmc
6. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215–1228.
crossref pmid pmc
7. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010;17:443–454.
crossref pmid pmc
8. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239–243.
crossref pmid pmc pdf
9. Park ES, Kim SJ, Kim SW, Yoon SL, Leem SH, Kim SB, et al. Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci U S A 2011;108:17456–17461.
crossref pmid pmc
10. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754–1760.
crossref pmid pmc pdf
11. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297–1303.
crossref pmid pmc
12. Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 2012;28:1811–1817.
crossref pmid pdf
13. Li M, Stoneking M. A new approach for detecting low-level mutations in next-generation sequence data. Genome Biol 2012;13:R34.
crossref pmid pmc
14. Alioto TS, Buchhalter I, Derdak S, Hutter B, Eldridge MD, Hovig E, et al. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nat Commun 2015;6:10001.
crossref pmid pmc pdf
15. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013;45:977–983.
crossref pmid pmc pdf
16. Rubin MA, Demichelis F. The genomics of prostate cancer: a historic perspective. Cold Spring Harb Perspect Med 2018 Apr 30 [Epub]. .
17. Hovelson DH, Tomlins SA. The role of next-generation sequencing in castration-resistant prostate cancer treatment. Cancer J 2016;22:357–361.
crossref pmid pmc


Browse all articles >

Editorial Office
Room No. 806, 193 Mallijae-ro, Jung-gu, Seoul 04501, Korea
Tel: +82-2-558-9394    Fax: +82-2-558-9434    E-mail:                

Copyright © 2024 by Korea Genome Organization.

Developed in M2PI

Close layer
prev next